Sun Pharma rolls out Absorica LD

Patients with severe acne have a lower dose isotretinoin option available, now that Sun Pharma is introducing Absorica LD (isotretinoin) capsules.

The product is indicated for the management of severe recalcitrant nodular acne in patients 12 years of age and older. Absorica LD is the only isotretinoin formulation to feature Sun Pharma’s micronization technology, which utilizes micronized particles to optimize absorption at a 20% lower dose, the company said.

“The launch of Absorica LD — which offers the proven efficacy and safety of Absorica at a lower dose — underscores our commitment to making a difference in the lives of people with severe recalcitrant nodular acne,” Abhay Gandhi, Sun Pharma North America CEO said.

“Severe recalcitrant nodular acne is characterized by nodules, which are hard, solid, painful lumps in the skin, and primarily affects teens and young adults,” Nicholas Squittieri, Sun Pharma North America chief medical officer said. “Ineffective acne treatment can cause lifelong physical scars as well as psychosocial issues such as feelings of isolation. Absorica LD makes visibly clearer skin possible within just five months, removes the uncertainty surrounding timing of dosing, and makes absorption more predictable. The availability of a low-dose, highly bioavailable oral isotretinoin option should be welcome news for those suffering from this very severe form of acne.”